Valneva SE/€VLA
1D1W1MYTD1Y5YMAX
Capital at risk
About Valneva SE
Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases. The company's portfolio includes vaccines for diseases such as Japanese encephalitis and cholera. Valneva is actively engaged in developing vaccines for Lyme disease and chikungunya. Founded in 2013 through the merger of Intercell AG and Vivalis, Valneva is headquartered in Saint-Herblain, France. The company operates primarily in Europe but has a global reach through various strategic partnerships and licensing agreements. Valneva's competitive strength lies in its focus on addressing unmet medical needs with its diverse pipeline of innovative vaccine candidates.
- Ticker
- €VLA
- Sector
- Health
- Primary listing
- PAR
- Employees
- 620
- Headquarters
- Saint-Herblain, France
- Website
- valneva.com
Valneva SE Metrics
BasicAdvanced
€545M
-
-€0.88
1.37
-
Price and volume
Market cap
€545M
Beta
1.37
52-week high
€5.20
52-week low
€2.03
Average daily volume
1.3M
Financial strength
Current ratio
2.157
Quick ratio
1.334
Long term debt to equity
2.331
Total debt to equity
2.592
Interest coverage (TTM)
-2.83%
Profitability
EBITDA (TTM)
-98.721
Gross margin (TTM)
-41.73%
Net profit margin (TTM)
-110.29%
Operating margin (TTM)
-80.38%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
€230,000
Management effectiveness
Return on assets (TTM)
-16.68%
Return on equity (TTM)
-117.85%
Valuation
Price to revenue (TTM)
3.596
Price to book
6.72
Price to tangible book (TTM)
9.06
Price to free cash flow (TTM)
-8.856
Free cash flow yield (TTM)
-11.29%
Free cash flow per share (TTM)
-0.325
Growth
Revenue change (TTM)
-27.19%
Earnings per share change (TTM)
107.91%
3-year revenue growth (CAGR)
-30.49%
10-year revenue growth (CAGR)
4.11%
3-year earnings per share growth (CAGR)
156.99%
10-year earnings per share growth (CAGR)
0.57%
Bulls say / Bears say
Pfizer and Valneva reported more than 70% efficacy for the investigational Lyme vaccine in Phase 3, with Pfizer planning regulatory submissions; successful approval could create a significant new revenue stream. (Pfizer)
Valneva ended June with €121.5 million in cash, reaffirmed 2026 product-sales guidance of €135 million to €150 million, and expects restructuring to improve profitability and cash flow in the second half. (SEC)
The company completed an €84 million reserved offering, including €37 million received at closing and up to €47 million from warrant exercise, providing additional funding for its vaccine pipeline and commercial operations. (Euronext)
The Lyme vaccine candidate showed 73.2% efficacy, but the primary endpoint’s prespecified statistical criterion was not met because fewer cases occurred than expected, leaving regulatory approval and commercial timing uncertain. (Bloomberg)
Valneva withdrew its U.S. IXCHIQ application after the FDA suspended the vaccine’s license, and the FDA subsequently recorded the company’s discontinuation of U.S. IXCHIQ manufacturing and voluntary license revocation. (FDA)
First-half 2026 revenue fell to €65.8 million from €97.6 million, while net loss widened to €63.3 million and product-level gross margin declined sharply, highlighting substantial earnings pressure. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Upcoming events
No upcoming events
Funds containing Valneva SE
AllUSDEURGBP
Fund name | Fund size | €VLA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.05% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.05% |
iShares Healthcare Innovation£DRDR | £1B | 0.05% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.